Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
This product is a CHO-S stable cell line. It stably expresses Human IL2RA to provide cell models for research and screening applications.
Product Information
Target Protein
IL2RA
Target Protein Species
Human
Accession Number
NM_000417.3
Protein Tag
Tag-free
Host Cell Type
CHO-S
Target Classification
Immune Checkpoint
Target Family
Immune Checkpoint
Target Research Area
Autoimmune Research; Immunology Research
Related Diseases
Immunodeficiency; Diabetes Mellitus
Product Properties
Morphology
Suspension
Assay Types
Drug screening and biological assays
Resistance
Puromycin
Mycoplasma Testing
Negative
Sterility Testing
10 passages
Biosafety Level
Level 1
Activity
Yes
Quantity
5x10⁶ cells
Form
Frozen cells
Freeze Medium
90% EX-Cell CD CHO Fusion + 10% DMSO
Culture Medium
EX-Cell CD CHO Fusion + 10µg/mL Puromycin
Selective Antibiotic(s)
Regular antibiotics active against mycoplasmas, bacteria and fungi.
Handling Notes
Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance. Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line. Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
Incubation
37°C with 5% CO₂
Applications
Drug screening and biological assays
Application Notes
Cells were plated in a 384-well plate and incubated overnight at 37°C and 5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control for high-throughput drugs screening andfunctional assays.
Use Restrictions
These cells are distributed for research use only.
Shipping
Dry ice
Storage
Liquid nitrogen
Target
Full Name
Interleukin 2 receptor subunit alpha
Introduction
The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. Patients with severe Coronavirus Disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have significantly elevated levels of IL2R in their plasma. Similarly, serum IL-2R levels are found to be elevated in patients with different types of carcinomas. Certain IL2RA and IL2RB gene polymorphisms have been associated with lung cancer risk.